Cargando…

Dysregulation of TLR2 Serves as a Prognostic Biomarker in Breast Cancer and Predicts Resistance to Endocrine Therapy in the Luminal B Subtype

Background: Breast cancer (BCa) is a serious global health burden among females, and the development of resistance represents an important challenge to BCa treatment. Here, we examined the expression of toll-like receptor 2 (TLR2) in BCa patients and the prognostic value of TLR2 for predicting endoc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yunmei, Liu, Shuguang, Zhang, Yanjun, Yang, Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203473/ https://www.ncbi.nlm.nih.gov/pubmed/32426275 http://dx.doi.org/10.3389/fonc.2020.00547

Ejemplares similares

Association of Obesity and Luminal Subtypes in Prognosis and Adjuvant Endocrine Treatment Effectiveness Prediction in Chinese Breast Cancer Patients
por: Tong, Yiwei, et al.
Publicado: (2022)

SIRT7 Is a Prognostic Biomarker Associated With Immune Infiltration in Luminal Breast Cancer
por: Huo, Qin, et al.
Publicado: (2020)

Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping
por: Whitworth, Pat, et al.
Publicado: (2016)

RNA m(6)A Methylation Regulators Subclassify Luminal Subtype in Breast Cancer
por: Yang, Lin, et al.
Publicado: (2021)

Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis
por: Diana, Anna, et al.
Publicado: (2022)

Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients
por: Hashmi, Atif Ali, et al.
Publicado: (2018)

MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours
por: Green, Andrew R, et al.
Publicado: (2016)

Comprehensive Transcriptomic Analysis Reveals Dysregulated Competing Endogenous RNA Network in Endocrine Resistant Breast Cancer Cells
por: Gao, Liang, et al.
Publicado: (2020)

ITGA3 Is Associated With Immune Cell Infiltration and Serves as a Favorable Prognostic Biomarker for Breast Cancer
por: Li, Yue, et al.
Publicado: (2021)

Molecular Mechanism of Secondary Endocrine Resistance in Luminal Breast Cancer
por: Wu, Minhua, et al.
Publicado: (2021)

Inflammation-related parameter serve as prognostic biomarker in esophageal squamous cell carcinoma
por: Xu, Xiaoqin, et al.
Publicado: (2022)

CXCL12 and CXCR4 as Potential Early Biomarkers for Luminal A and Luminal B Subtypes of Breast Cancer
por: Motyka, Joanna, et al.
Publicado: (2023)

Integrin-β6 Serves as a Potential Prognostic Serum Biomarker for Gastric Cancer
por: Li, Zequn, et al.
Publicado: (2021)

The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy
por: De Santo, Irene, et al.
Publicado: (2019)

The CSRNP Gene Family Serves as a Prognostic Biomarker in Clear Cell Renal Cell Carcinoma
por: Zhang, Huaru, et al.
Publicado: (2021)

SRSF3 Expression Serves as a Potential Biomarker for Prognostic and Immune Response in Pan-Cancer
por: Li, Zihua, et al.
Publicado: (2022)

Path to Clonal Theranostics in Luminal Breast Cancers
por: Hajjaji, Nawale, et al.
Publicado: (2022)

Comparison of endocrine therapy and chemotherapy as different systemic treatment modes for metastatic luminal HER2-negative breast cancer patients —A retrospective study
por: Liu, Qiuyue, et al.
Publicado: (2022)

Plasma-Derived Extracellular Vesicles Circular RNAs Serve as Biomarkers for Breast Cancer Diagnosis
por: Lin, Li, et al.
Publicado: (2021)

Androgens in Patients With Luminal B and HER2 Breast Cancer Might Be a Biomarker Promoting Anti-PD-1 Efficacy
por: Li, Peng, et al.
Publicado: (2022)

ASRGL1 Correlates With Immune Cell Infiltration in Hepatocellular Carcinoma and Can Serve as a Prognostic Biomarker
por: Xue, Cailin, et al.
Publicado: (2021)

Identification of prognostic biomarkers in papillary renal cell carcinoma and PTTG1 may serve as a biomarker for predicting immunotherapy response
por: Tian, Xi, et al.
Publicado: (2022)

Development and validation of an ultrasound-based radiomics nomogram for predicting the luminal from non-luminal type in patients with breast carcinoma
por: Wu, Jiangfeng, et al.
Publicado: (2022)

E2F2/5/8 Serve as Potential Prognostic Biomarkers and Targets for Human Ovarian Cancer
por: Zhou, Quan, et al.
Publicado: (2019)

Extra Spindle Pole Bodies-Like 1 Serves as a Prognostic Biomarker and Promotes Lung Adenocarcinoma Metastasis
por: Nie, Zhi, et al.
Publicado: (2022)

Association Between Insulin Resistance and Luminal B Subtype Breast Cancer in Postmenopausal Women
por: Nam, Sanggeun, et al.
Publicado: (2016)

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer
por: Grote, Isabel, et al.
Publicado: (2021)

p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer
por: Halim, Freda, et al.
Publicado: (2022)

Illuminating luminal B: QSOX1 as a subtype-specific biomarker
por: Das, Padmalaya, et al.
Publicado: (2013)

Unfolding the Role of Stress Response Signaling in Endocrine Resistant Breast Cancers
por: Clarke, Robert, et al.
Publicado: (2015)

MECOM/PRDM3 and PRDM16 Serve as Prognostic-Related Biomarkers and Are Correlated With Immune Cell Infiltration in Lung Adenocarcinoma
por: Li, Meng, et al.
Publicado: (2022)

Prognostic Value of NLRP3 Inflammasome and TLR4 Expression in Breast Cancer Patients
por: Saponaro, Concetta, et al.
Publicado: (2021)

Predictive and Prognostic Brain Metastases Assessment in Luminal Breast Cancer Patients: FN14 and GRP94 from Diagnosis to Prophylaxis
por: Martínez-Aranda, Antonio, et al.
Publicado: (2017)

Prognostic Significance of Neutrophil-to-Lymphocyte Ratio and C-Reactive Protein/Albumin Ratio in Luminal Breast Cancers With HER2-Negativity
por: Chen, Fei, et al.
Publicado: (2022)

Identification of prognostic cancer-associated fibroblast markers in luminal breast cancer using weighted gene co-expression network analysis
por: Xu, An, et al.
Publicado: (2023)

AMPD1 Is Associated With the Immune Response and Serves as a Prognostic Marker in HER2-Positive Breast Cancer
por: Wang, Long, et al.
Publicado: (2021)

Integrative Analysis of Novel Metabolic Subtypes in Pancreatic Cancer Fosters New Prognostic Biomarkers
por: Follia, Laura, et al.
Publicado: (2019)

Comprehensive proteome, phosphoproteome and kinome characterization of luminal A breast cancer
por: Yang, Ganglong, et al.
Publicado: (2023)

Identification of Tumor Microenvironment-Related Prognostic Biomarkers in Luminal Breast Cancer
por: Wang, Yanyan, et al.
Publicado: (2020)

“Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now?”
por: Höller, Anna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qq3vq2hdt4natagg5eugealjcs